• ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • ASSAYS
    • By Receptor
    • By Disease State
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Toxicology Solutions
      • In Vitro Toxicology Platform
      • Gene Expression
      • MDR1 / Human P-Glycoprotein
      • Discovery Toxicology
      • Environmental Monitoring
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
    • Ortholog Assays
    • Custom Assay Development
  • TECHNOLOGY
    • Nuclear Receptor Overview
    • Assay Kit Platform & Formats
    • Nuclear Receptor Profiling & Panels
    • Environmental Testing Solutions
    • Growth Factor Receptors
    • upcyte® Hepatocytes
    • FAQ
  • RESOURCES
    • Technical Manuals
    • Safety Data Sheets
    • Scientific Whitepapers from INDIGO
    • Scientific Posters
    • New Research Publications
    • Nuclear Receptor Resource
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Request Information
    • Distributors
    • Terms & Conditions
      • Product Policies
      • Limited Use Disclosures
  • BLOG
Search site...

± α β γ δ Δ ε ζ κ ω ö ® ™ µ

  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • ASSAYS
    • By Receptor
    • By Disease State
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Toxicology Solutions
      • In Vitro Toxicology Platform
      • Gene Expression
      • MDR1 / Human P-Glycoprotein
      • Discovery Toxicology
      • Environmental Monitoring
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
    • Ortholog Assays
    • Custom Assay Development
  • TECHNOLOGY
    • Nuclear Receptor Overview
    • Assay Kit Platform & Formats
    • Nuclear Receptor Profiling & Panels
    • Environmental Testing Solutions
    • Growth Factor Receptors
    • upcyte® Hepatocytes
    • FAQ
  • RESOURCES
    • Technical Manuals
    • Safety Data Sheets
    • Scientific Whitepapers from INDIGO
    • Scientific Posters
    • New Research Publications
    • Nuclear Receptor Resource
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Request Information
    • Distributors
    • Terms & Conditions
      • Product Policies
      • Limited Use Disclosures
  • BLOG
Print Friendly, PDF & Email

Dog Farnesoid X Receptor (dFXR; nr1h4)

Product Family Product Number Product Description Technical Manual
D0060
dFXR
(nr1h4)
D00601-32 Dog FXR Reporter Assay System, 3 x 32 assays in 96-well format Technical Manual
D00601 Dog FXR Reporter Assay System, 1 x 96-well format assays Technical Manual

Get Pricing

  • Kits
  • Services
  • Background
  • Research Areas

Dog Farnesoid X Receptor Assay Kit

This Dog Farnesoid X Receptor (dFXR)assay kit is an all-inclusive firefly luciferase reporter assay system that includes in addition to dFXR Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.

dFXR Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.

INDIGO’s assay kits feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.

Kits are offered in different assay formats to accommodate researchers’ needs: 3 x 32 and 1 x 96 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications.

Assay Kit & Platforms

Bulk assay reagents can be custom manufactured to accommodate any scale of HTS. Please inquire.

FXR assay kits also available in: Human, Mouse, Rat, Cyn Monkey

Dog Farnesoid X Receptor Assay Services

The primary application of INDIGO’s cell-based nuclear receptor assays are to quantitatively assess the bioactivity of a test compound as an agonist (activator) or antagonist (inhibition of an agonist response) of a given receptor. Service assays include a positive control reference compound and ‘vehicle’ control for every experiment. A formal study report and all data files are provided to the client upon completion of the study. To receive a quote for your proposed study, complete & submit the online “Request a Quote” form, or, contact an INDIGO Customer Service Representative to discuss your desired study parameters.

FXR Service Assays: Human, Mouse, Rat, Cyn Monkey, Dog

Dog Farnesoid X Receptor Assay Background

The Farnesoid X Receptor (FXR), also known as NR1H4 is a nuclear hormone receptor with activity similar to that seen in other steroid receptors such as estrogen or progesterone receptor, but more similar in form to PPAR, LXR, and RXR. FXR is expressed at high levels in the liver and intestine. Chenodeoxycholic acid and other bile acids are natural ligands for FXR.

Like other steroid receptors, when activated, FXR translocates to the cell nucleus, forms a heterodimer with RXR and binds to hormone response elements on DNA (FXEs) to elicit expression or transrepression of gene products. One of the primary functions of FXR activation is the suppression of cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis from cholesterol. FXR does not directly bind to the CYP7A1 promoter. Rather, FXR induces expression of small heterodimer partner (SHP) which then functions to inhibit transcription of the CYP7A1 gene. In this way a negative feedback pathway is established in which synthesis of bile acids is inhibited when cellular levels are already high.

These Dog FXR Reporter Assay Systems utilize non-human mammalian cells engineered to express Dog NR1H4 protein, commonly referred to as dFXR.

The principle application of this assay product is in the screening of test samples to quantify functional activities, either agonist or antagonist, that they may exert against the dogy farnesoid x receptor.

For more information about FXR, visit the Nuclear Receptor Resource

Dog Farnesoid X Receptor Assay Research Areas

Dyslipidemia; Bile Acid and Xenobiotic; Metabolic Disease; Toxicology; NASH/NAFLD; Drug-Nutrient Interaction

Research articles associated with FXR

Request a Quote Icon
Search site...
Click to Insert Symbols in Search

α β γ δ Δ ε ζ κ ® ™ µ

Want More Information?

Resource Quick Links

  • Technical Manuals & Product Listing
  • Safety Data Sheets
  • Sample Study Report
  • Study Work Order Form

3006 Research Drive, Suite A1, State College, PA, USA 16801

+1 (814) 234-1919

  • Home
  • Products
  • Request a Quote
  • FAQ

© 2022 INDIGO Biosciences, Inc. All Rights Reserved